Bradykinin receptor ligands: therapeutic perspectives

Kinins, which are produced by the action of kallikrein enzymes, are blood-derived local-acting peptides that have broad effects mediated by two related G-protein-coupled receptors termed the bradykinin receptors. The endogenous kallikrein–kinin system controls blood circulation and kidney function, and promotes inflammation and pain in pathological conditions, which has led to interest in developing modulators of bradykinin receptors as potential therapeutics. This review discusses recent progress in our understanding of the genetics, molecular biology and pathophysiology of kinins and their receptors, as well as developments in medicinal chemistry, which have brought us closer to therapeutic applications of kinin receptor ligands in various indications. The potential of kinin receptor antagonists as novel analgesic agents that do not result in tolerance or have a liability for abuse has attracted particular interest.

[1]  C. Teixeira,et al.  Contribution of B2 receptors for bradykinin in Arthus reaction‐induced plasma extravasation in wild‐type or B2 transgenic knockout mice , 2000, British journal of pharmacology.

[2]  H. Drexler,et al.  AT1-Receptor Antagonism Improves Endothelial Function in Coronary Artery Disease by a Bradykinin/B2-Receptor-Dependent Mechanism , 2003, Hypertension.

[3]  C. Strader,et al.  Expression cloning of a human B1 bradykinin receptor. , 1994, The Journal of biological chemistry.

[4]  D. Pruneau,et al.  Pharmacological profile of LF 16-0687, a new potent non-peptide bradykinin B2 receptor antagonist. , 1999, Immunopharmacology.

[5]  D. Bachvarov,et al.  The B1 receptors for kinins. , 1998, Pharmacological reviews.

[6]  J. Isner,et al.  Targeting Kinin B1 Receptor for Therapeutic Neovascularization , 2002, Circulation.

[7]  J. Pesquero,et al.  Structure of the mammalian kinin receptor gene locus. , 2002, International immunopharmacology.

[8]  W. Neugebauer,et al.  Kinin B1 receptor antagonists with multi-enzymatic resistance properties. , 2002, Canadian journal of physiology and pharmacology.

[9]  K. Nakahara,et al.  The identification of an orally active, nonpeptide bradykinin B2 receptor antagonist, FR173657 , 1997, British journal of pharmacology.

[10]  Michele Simonato,et al.  Autoradiographic analysis of rat brain kinin B1 and B2 receptors: Normal distribution and alterations induced by epilepsy , 2003, The Journal of comparative neurology.

[11]  W. König,et al.  Hoe 140 a new potent and long acting bradykinin‐antagonist: in vivo studies , 1991, British journal of pharmacology.

[12]  H. Margolius.  Tissue kallikreins structure, regulation, and participation in mammalian physiology and disease , 1998, Clinical reviews in allergy & immunology.

[13]  P. Sirois,et al.  Implication of the bradykinin receptors in antigen‐induced pulmonary inflammation in mice , 2003, British journal of pharmacology.

[14]  C. Strader,et al.  Targeted Disruption of a B2 Bradykinin Receptor Gene in Mice Eliminates Bradykinin Action in Smooth Muscle and Neurons (*) , 1995, The Journal of Biological Chemistry.

[15]  A. Danser,et al.  Mediators of Bradykinin-Induced Vasorelaxation in Human Coronary Microarteries , 2004, Hypertension.

[16]  J. Stewart,et al.  Competitive antagonists of bradykinin , 1985, Peptides.

[17]  K. Jarnagin,et al.  Expression cloning of a rat B2 bradykinin receptor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[18]  F. Legat,et al.  Effects of the non-peptide B2 receptor antagonist FR173657 in models of visceral and cutaneous inflammation , 2000, Inflammation Research.

[19]  O. Carretero,et al.  Effect of high salt intake in mutant mice lacking bradykinin-B2 receptors. , 1997, Hypertension.

[20]  D. Brooks,et al.  The Effect of Acute Angiotensin-Converting Enzyme and Neutral Endopeptidase 24.11 Inhibition on Plasma Extravasation in the Rat , 2004, Journal of Pharmacology and Experimental Therapeutics.

[21]  M. Bock,et al.  Generation and Characterization of a Human Bradykinin Receptor B1 Transgenic Rat as a Pharmacodynamic Model , 2004, Journal of Pharmacology and Experimental Therapeutics.

[22]  R. Gazzinelli.  Faculty Opinions recommendation of Cutting edge: bradykinin induces IL-12 production by dendritic cells: a danger signal that drives Th1 polarization. , 2003 .

[23]  A. Schmaier.  The physiologic basis of assembly and activation of the plasma kallikrein/kinin system , 2004, Thrombosis and Haemostasis.

[24]  P. McIntyre,et al.  Potent and orally bioavailable non-peptide antagonists at the human bradykinin B(1) receptor based on a 2-alkylamino-5-sulfamoylbenzamide core. , 2004, Journal of medicinal chemistry.

[25]  P. Narotam,et al.  Traumatic Brain Contusions: A Clinical Role for the Kinin Antagonist CP-0127 , 1998, Acta Neurochirurgica.

[26]  J. Reid,et al.  Bradykinin B(2) receptor antagonism attenuates blood pressure response to acute angiotensin-converting enzyme inhibition in normal men. , 2000, Hypertension.

[27]  D. Bachvarov,et al.  Agonist-induced translocation of the kinin B(1) receptor to caveolae-related rafts. , 2002, Molecular pharmacology.

[28]  A. Schmaier,et al.  Mapping the Interaction between High Molecular Mass Kininogen and the Urokinase Plasminogen Activator Receptor* , 2004, Journal of Biological Chemistry.

[29]  W. Neugebauer,et al.  Kinin B1 receptor antagonists containing alpha-methyl-L-phenylalanine: in vitro and in vivo antagonistic activities. , 1999, Hypertension.

[30]  M. Bock,et al.  Discovery of a potent, non-peptide bradykinin B1 receptor antagonist. , 2003, Journal of the American Chemical Society.

[31]  Michael Bader,et al.  Role of Bradykinin B2 and B1 Receptors in the Local, Remote, and Systemic Inflammatory Responses That Follow Intestinal Ischemia and Reperfusion Injury1 , 2004, The Journal of Immunology.

[32]  J. Stewart,et al.  New bradykinin antagonists having very high potency at B1 receptors. , 1996, Immunopharmacology.

[33]  R. Bartus,et al.  The Development of the Bradykinin Agonist Labradimil as a Means to Increase the Permeability of the Blood-Brain Barrier , 2001, Clinical pharmacokinetics.

[34]  D. Zochodne,et al.  Increased mRNA expression of the B1 and B2 bradykinin receptors and antinociceptive effects of their antagonists in an animal model of neuropathic pain , 2000, Pain.

[35]  N. Plesnila,et al.  Effects of LF 16-0687 Ms, a bradykinin B2 receptor antagonist, on brain edema formation and tissue damage in a rat model of temporary focal cerebral ischemia , 2002, Brain Research.

[36]  A. Sher,et al.  Cutting Edge: Bradykinin Induces IL-12 Production by Dendritic Cells: A Danger Signal That Drives Th1 Polarization1 , 2003, The Journal of Immunology.

[37]  M. Carattino,et al.  The involvement of kallikrein-kinin system in diabetes type I (insulitis). , 1999, Immunopharmacology.

[38]  W. Müller-Esterl,et al.  Overexpression and functional characterization of kinin receptors reveal subtype-specific phosphorylation. , 1999, Biochemistry.

[39]  J. Morrow,et al.  Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. , 1998, The New England journal of medicine.

[40]  R. Colman,et al.  Immunolocalization and Expression of Kallistatin and Tissue Kallikrein in Human Inflammatory Bowel Disease , 2003, Digestive Diseases and Sciences.

[41]  A. Adam,et al.  Angiotensin-Converting Enzyme Inhibitor-Associated Angioedema Is Characterized by a Slower Degradation of des-Arginine9-Bradykinin , 2002, Journal of Pharmacology and Experimental Therapeutics.

[42]  T. Unger,et al.  Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. , 1995, Pharmacological reviews.

[43]  R. Ye,et al.  Up-Regulation of Functional Kinin B1 Receptors in Allergic Airway Inflammation1 , 2002, The Journal of Immunology.

[44]  E. Hawe,et al.  Variation in bradykinin receptor genes increases the cardiovascular risk associated with hypertension. , 2003, European heart journal.

[45]  P. Soubrié,et al.  SSR240612 [(2R)-2-[((3R)-3-(1,3-Benzodioxol-5-yl)-3-{[(6-methoxy-2-naphthyl)sulfonyl]amino}propanoyl)amino]-3-(4-{[2R,6S)-2,6-dimethylpiperidinyl]methyl}phenyl)-N-isopropyl-N-methylpropanamide Hydrochloride], a New Nonpeptide Antagonist of the Bradykinin B1 Receptor: Biochemical and Pharmacological , 2004, Journal of Pharmacology and Experimental Therapeutics.

[46]  J. Gougat.  SSR240612 [(2R)-2-[((3R)-3-(1,3-Benzodioxol-5-yl)-3- propanoyl)amino]-3-(4- phenyl)-N-isopropyl-N-methylpropanamide Hydrochloride], a New Nonpeptide Antagonist of the Bradykinin B1 Receptor: Biochemical and Pharmacological Characterization , 2004 .

[47]  W. König,et al.  Hoe 140 a new potent and long acting bradykinin‐antagonist: in vitro studies , 1991, British journal of pharmacology.

[48]  J. Rouleau,et al.  The kallikrein-kininogen-kinin system: lessons from the quantification of endogenous kinins , 2000, Peptides.

[49]  K. Varani,et al.  Changes in hippocampal and cortical B1 bradykinin receptor biological activity in two experimental models of epilepsy , 1999, Neuroscience.

[50]  P. McIntyre,et al.  Bradyzide, a potent non‐peptide B2 bradykinin receptor antagonist with long‐lasting oral activity in animal models of inflammatory hyperalgesia , 2000, British journal of pharmacology.

[51]  J. Stewart,et al.  Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a “biased agonist” mechanism , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[52]  J. Winter,et al.  Bradykinin B1 receptor is constitutively expressed in the rat sensory nervous system , 2000, Neuroscience Letters.

[53]  M. Iwai,et al.  ACE Inhibitor Improves Insulin Resistance in Diabetic Mouse Via Bradykinin and NO , 2002, Hypertension.

[54]  J. Stewart.  Bradykinin antagonists: discovery and development , 2004, Peptides.

[55]  T. Walther,et al.  Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[56]  M. Teixeira,et al.  Kinin B 1 Receptor Up-Regulation after Lipopolysaccharide Administration : Role of Proinflammatory Cytokines and Neutrophil Influx 1 , 2004 .

[57]  J. Rouleau,et al.  Vasopeptidase Inhibitor Omapatrilat Induces Profound Insulin Sensitization and Increases Myocardial Glucose Uptake in Zucker Fatty Rats: Studies Comparing a Vasopeptidase Inhibitor, Angiotensin-Converting Enzyme Inhibitor, and Angiotensin II Type I Receptor Blocker , 2003, Circulation.

[58]  D. Vaughan,et al.  Angiotensin-Converting Enzyme Inhibition Increases Human Vascular Tissue-Type Plasminogen Activator Release Through Endogenous Bradykinin , 2003, Circulation.

[59]  D. Bachvarov,et al.  Bradykinin B(2) receptor endocytosis, recycling, and down-regulation assessed using green fluorescent protein conjugates. , 2001, The Journal of pharmacology and experimental therapeutics.

[60]  A. Artru,et al.  LF 16-0687 Ms, a bradykinin B2 receptor antagonist, reduces brain edema and improves long-term neurological function recovery after closed head trauma in rats. , 2002, Journal of neurotrauma.

[61]  R. Colman,et al.  Bradykinin receptor antagonists type 2 attenuate the inflammatory changes in peptidoglycan-induced acute arthritis in the Lewis rat , 2001, Inflammation Research.

[62]  D. Regoli,et al.  Pharmacology of bradykinin and related kinins. , 1980, Advances in experimental medicine and biology.

[63]  M. Majima,et al.  AT2 receptor‐dependent vasodilation is mediated by activation of vascular kinin generation under flow conditions , 2002 .

[64]  M. Teixeira,et al.  Kinin B1 Receptor Up-Regulation after Lipopolysaccharide Administration: Role of Proinflammatory Cytokines and Neutrophil Influx1 , 2004, The Journal of Immunology.

[65]  G. Bakris,et al.  Effects of COX Inhibition on Blood Pressure and Kidney Function in ACE Inhibitor-Treated Blacks and Hispanics , 2004, Hypertension.

[66]  Q. Ma,et al.  Basal expression of bradykinin B1 receptor in the spinal cord in humans and rats , 2001, Neuroreport.